Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intismeran autogene
- Development stage
- Phase 3
- Lead developer
- Merck
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Intismeran autogene (mRNA-4157/V940) is an investigational, personalized mRNA-based individualized neoantigen therapy (INT) being co-developed by Moderna and Merck (MSD). It is designed to stimulate a patient-specific immune response by encoding up to 34 unique neoantigens identified through genomic sequencing of the patient's resected tumor. Using a proprietary algorithm, the therapy selects the most immunogenic neoantigens, which are then delivered via mRNA encapsulated in lipid nanoparticles. Once administered, the mRNA is translated endogenously, allowing the immune system to recognize and prime T cells against the specific mutations present in the patient's cancer. In the context of renal cell carcinoma, it is being evaluated as an adjuvant treatment in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab to prevent disease recurrence following complete resection.
- Brand names
- mRNA-4157/V940
- Other names
- mRNA-4157mRNA4157mRNA 4157V940V-940V 940
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on intismeran autogene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intismeran autogene.